	US 11,866,502 B2
	Anti-FGFR2 antibodies and methods of use thereof
Christopher Daly, New York, NY (US); Frank Delfino, Poughquag, NY (US); Amy Han, Hockessin, DE (US); Thomas Nittoli, Pearl River, NY (US); and Li Zhang, Baldwin Place, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Oct. 21, 2021, as Appl. No. 17/507,138.
Claims priority of provisional application 63/253,858, filed on Oct. 8, 2021.
Claims priority of provisional application 63/220,948, filed on Jul. 12, 2021.
Claims priority of provisional application 63/104,377, filed on Oct. 22, 2020.
Prior Publication US 2022/0162323 A1, May 26, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2863 (2013.01) [A61K 45/06 (2013.01); A61K 47/6849 (2017.08); A61P 35/00 (2018.01); C07K 16/30 (2013.01); A61K 2039/505 (2013.01)]

65 Claims

1. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to FGFR2, wherein the antibody or antigen-binding fragment thereof

comprises three heavy chain CDRs (HCDR1, HCDR2, and HCDR3) contained within the heavy chain variable region (HCVR) amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 22, and three light chain CDRs (LCDR1, LCDR2, and LCDR3) contained within the light chain variable region (LCVR) amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 28.